S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Price, News & Analysis

$6.17
-0.42 (-6.37%)
(As of 03/4/2024 ET)
Today's Range
$6.10
$6.67
50-Day Range
$4.09
$6.59
52-Week Range
$3.80
$10.27
Volume
1.24 million shs
Average Volume
732,163 shs
Market Capitalization
$191.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

PDS Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
186.3% Upside
$17.67 Price Target
Short Interest
Healthy
16.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of PDS Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.44) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.43 out of 5 stars

Medical Sector

764th out of 960 stocks

Pharmaceutical Preparations Industry

350th out of 440 stocks


PDSB stock logo

About PDS Biotechnology Stock (NASDAQ:PDSB)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Stock Price History

PDSB Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
PDSB Jan 2024 7.500 call
PDSB Jan 2024 7.500 put
PDSB Feb 2024 7.500 call
PDS Biotechnology Appoints Lars Boesgaard To Succeed Matthew Hill As CFO
PDS Biotechnology: Q3 Earnings Insights
A Preview Of PDS Biotechnology's Earnings
See More Headlines
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/05/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PDSB
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.67
High Stock Price Target
$21.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+186.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-40,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.55 per share

Miscellaneous

Free Float
27,997,000
Market Cap
$191.95 million
Optionable
Optionable
Beta
1.72
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Frank K. Bedu-Addo Ph.D. (Age 59)
    President, CEO & Director
    Comp: $854.1k
  • Mr. Lars Robert Boesgaard M.B.A. (Age 54)
    Chief Financial Officer
  • Dr. Joe J. Dervan
    VP of Research & Development
  • Dr. Gregory L. Conn Ph.D. (Age 69)
    Chief Scientific Officer
    Comp: $220.46k
  • Ms. Deanne Randolph
    Head of Investor Relations
  • Mr. Spencer Brown J.D. (Age 54)
    Senior VP & General Counsel
  • Dr. Kirk V. Shepard M.D.
    Chief Medical Officer
  • Ms. Janetta Trochimiuk (Age 61)
    Controller














PDSB Stock Analysis - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings
or view top-rated stocks.

What is PDS Biotechnology's stock price target for 2024?

4 analysts have issued twelve-month price objectives for PDS Biotechnology's stock. Their PDSB share price targets range from $12.00 to $21.00. On average, they expect the company's share price to reach $17.67 in the next year. This suggests a possible upside of 186.3% from the stock's current price.
View analysts price targets for PDSB
or view top-rated stocks among Wall Street analysts.

How have PDSB shares performed in 2024?

PDS Biotechnology's stock was trading at $4.97 at the beginning of 2024. Since then, PDSB stock has increased by 24.1% and is now trading at $6.17.
View the best growth stocks for 2024 here
.

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PDSB earnings forecast
.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. During the same quarter in the previous year, the business earned ($0.23) EPS.

What other stocks do shareholders of PDS Biotechnology own?
Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.84%), Inspirion Wealth Advisors LLC (1.08%), Northern Trust Corp (0.80%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends
.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PDSB) was last updated on 3/5/2024 by MarketBeat.com Staff